Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
LINCOLN Pharmaceuticals's net profit margin of 13.2% in FY2025 reflects moderate profitability, with operating margin at 14.2% and gross margin at 53.3%.
In FY 2025, LINCOLN Pharmaceuticals posted a gross margin of 53.3%, an operating margin of 14.2%, a net margin of 13.2%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
LINCOLN Pharmaceuticals's revenue grew 7.4% to 6.23B in FY2025, but net profit declined 11.7% to 823.46M — indicating margin compression.
In FY 2025, LINCOLN Pharmaceuticals's revenue grew by 7.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
LINCOLN Pharmaceuticals's ROE of 12.3% in FY2025 indicates moderate shareholder returns.
In FY 2025, LINCOLN Pharmaceuticals reported an ROE of 12.3%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
LINCOLN Pharmaceuticals's FCF/NI ratio of 0.90x in FY2025 indicates reasonable cash generation relative to profits.
In FY 2025, LINCOLN Pharmaceuticals's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
LINCOLN Pharmaceuticals's OCF/NI ratio of 1.13x in FY2025 indicates sound cash management with earnings well-backed by cash.
In FY 2025, LINCOLN Pharmaceuticals's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
LINCOLN Pharmaceuticals's current ratio of 4.71x in FY2025 indicates ample liquidity, though assets may be underutilized.
In FY 2025, LINCOLN Pharmaceuticals reported a current ratio of 4.71. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
LINCOLN Pharmaceuticals's interest coverage ratio of 47.1x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, LINCOLN Pharmaceuticals reported an interest coverage ratio of 47.1x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
LINCOLN Pharmaceuticals's diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 20.03M.
In FY 2025, LINCOLN Pharmaceuticals's diluted shares remained flat by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025